Genincode PLC

Price Chart

Risk-Adjusted Performance

Genincode PLC (GENI) Price Performance

Genincode PLC (GENI) trades on London Stock Exchange in GBX. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at GBX1.20.

Over the past year, GENI has traded between a low of GBX1.02 and a high of GBX4.45. The stock has lost 51.0% over this period. It is currently 73.0% below its 52-week high.

Genincode PLC has a market capitalization of $8.70M.

About Genincode PLC

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

Compare Genincode PLC

Side-by-side comparison against top Healthcare peers.